Show simple item record

dc.contributor.authorBlancas López-Barajas, María Isabel 
dc.contributor.authorMartín-Pérez, Francisco J.
dc.contributor.authorGarrido Jiménez, José Manuel 
dc.contributor.authorRodríguez Serrano, Fernando 
dc.date.accessioned2021-03-03T09:18:22Z
dc.date.available2021-03-03T09:18:22Z
dc.date.issued2020-09-11
dc.identifier.citationI. Blancas, F.J. Martín-Pérez, J.M. Garrido et al. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients. The Breast 54 (2020) 106-113 [https://doi.org/10.1016/j.breast.2020.09.001]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/66803
dc.description.abstractBackground Trastuzumab is a drug used in HER2-positive breast cancer that increases patient survival. Due to cardiotoxicity is the most important side effect of trastuzumab treatment, cardiac monitoring should be a priority. The purpose of this study is to evaluate plasma NT-proBNP level and major cardiovascular risk factors as possible early predictors of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients. Methods We conducted a retrospective observational study involving 66 patients with HER2-positive breast cancer treated with trastuzumab. Left ventricle ejection fraction (LVEF), NT-proBNP values, and the history of cardiovascular risk factors were collected. Cardiotoxicity was diagnosed considering a decrease of the LVEF from baseline or clinical manifestation of congestive heart failure. NT-proBNP cut-off points were considered to establish normal or abnormal values according to patient age. Results 27.3% of the patients suffered cardiotoxicity during trastuzumab treatment. Most cases were diagnosed due to the appearance of cardiac symptomatology (66.7%). Logistic regression analysis showed a significant association of diabetes mellitus (OR 5.9, 95% CI 1.2–28.5, p = 0.028) and high NT-proBNP levels (OR 22.0, 95% CI 5.7–85.4, p < 0.0001) with the development of trastuzumab-induced cardiotoxicity. Conclusion NT-proBNP levels above the upper limit of the normal range adjusted to age or diabetes mellitus seem to be associated with a higher risk of developing cardiotoxicity. However, some limitations of the present study make necessary further studies aimed to clarify whether NT-proBNP and diabetes-associated markers determinations can be useful in the monitoring of cardiotoxicity risk in breast cancer patients undergoing trastuzumab therapy.es_ES
dc.description.sponsorshipRamon Areces Foundation, Madrid, Spaines_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectBreast canceres_ES
dc.subjectTrastuzumabes_ES
dc.subjectCardiotoxicityes_ES
dc.subjectHER-2es_ES
dc.subjectEarly diagnosises_ES
dc.subjectNT-proBNPes_ES
dc.titleNT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1016/j.breast.2020.09.001
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España